A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 24,500 shares of XFOR stock, worth $15,435. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,500
Previous 47,800 48.74%
Holding current value
$15,435
Previous $66,000 78.79%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.58 - $1.47 $437,575 - $1.11 Million
-754,441 Reduced 98.9%
8,413 $4,000
Q1 2024

May 15, 2024

SELL
$0.72 - $1.46 $694,951 - $1.41 Million
-965,211 Reduced 55.86%
762,854 $1.06 Million
Q4 2023

Feb 14, 2024

SELL
$0.61 - $0.99 $43,043 - $69,857
-70,563 Reduced 3.92%
1,728,065 $1.45 Million
Q3 2023

Nov 14, 2023

SELL
$1.03 - $2.02 $1.31 Million - $2.58 Million
-1,275,071 Reduced 41.48%
1,798,628 $1.96 Million
Q2 2023

Aug 14, 2023

BUY
$0.82 - $2.49 $2.51 Million - $7.61 Million
3,055,738 Added 17013.18%
3,073,699 $5.96 Million
Q1 2023

May 15, 2023

SELL
$0.8 - $1.22 $741,513 - $1.13 Million
-926,892 Reduced 98.1%
17,961 $15,000
Q4 2022

Feb 14, 2023

BUY
$0.69 - $2.21 $651,948 - $2.09 Million
944,853 New
944,853 $935,000
Q2 2022

Aug 15, 2022

SELL
$0.88 - $1.91 $9,028 - $19,596
-10,260 Reduced 18.48%
45,254 $44,000
Q1 2022

May 16, 2022

SELL
$1.48 - $2.58 $32,835 - $57,239
-22,186 Reduced 28.55%
55,514 $97,000
Q4 2021

Feb 14, 2022

BUY
$1.9 - $5.6 $83,159 - $245,100
43,768 Added 128.99%
77,700 $177,000
Q3 2021

Nov 15, 2021

SELL
$4.53 - $6.45 $59,528 - $84,759
-13,141 Reduced 27.92%
33,932 $180,000
Q2 2021

Aug 16, 2021

BUY
$6.49 - $9.56 $305,503 - $450,017
47,073 New
47,073 $305,000
Q2 2020

Aug 14, 2020

SELL
$7.98 - $10.44 $92,583 - $121,124
-11,602 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$6.03 - $11.01 $69,960 - $127,738
11,602 New
11,602 $116,000

Others Institutions Holding XFOR

About X4 Pharmaceuticals, Inc


  • Ticker XFOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,646,096
  • Market Cap $43.2M
  • Description
  • X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...
More about XFOR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.